+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
MALE
ID07863986

Predicting Response to Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients Using Imaging and Clinical Markers

Led by Lithuanian University of Health Sciences · Updated on 2026-10-14

70

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to identify factors that can predict the effectiveness of lutetium-177 PSMA radioligand therapy Pluvicto in treating metastatic castration-resistant prostate cancer mCRPC. The study focuses on how scan results, radiation dose measurements, and blood tests relate to reductions in prostate-specific antigen PSA levels and progression-free survival. Participants include patients receiving Pluvicto as part of routine care, and the study includes both new patients and those treated before the study began. Participants receive up to six cycles of Pluvicto infusions intravenously every six weeks, following approved treatment guidelines. They undergo baseline and follow-up PSMA PETCT scans, as well as multiple post-therapy SPECTCT scans after each treatment to measure radiation doses to tumors and organs. Additionally, blood samples are collected after each treatment to analyze tumor DNA, and quality of life questionnaires are completed periodically. All these procedures align with standard care and study-specific assessments. Throughout the study, participants have regular clinical evaluations including blood tests and imaging, with follow-up visits every four to six months after treatment ends. Researchers collect data on PSA response, progression-free survival, overall survival, adverse events, and quality of life changes. The study also uses existing medical records for retrospective analysis. Participants are monitored for up to five years to assess long-term outcomes and treatment response accuracy.

CONDITIONS

Brief Title

Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here